Subcutaneous Pembrolizumab Shows Non-inferiority to IV Pembrolizumab for Metastatic NSCLC
April 1, 2025LAURA Updated OS Data Support ‘New Standard of Care’ for Unresectable Stage III EGFR-Mutated NSCLC
March 28, 2025© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.